Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 54

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding

Faber, Erik B., Sun, Luxin, Tang, Jian, Roberts, Emily, Ganeshkumar, Sornakala, Wang, Nan, Rasmussen, Damien, Majumdar, Abir, Hirsch, Laura E., John, Kristen, Yang, An, Khalid, Hira, Hawkinson, Jon E., Levinson, Nicholas M., Chennathukuzhi, Vargheese, Harki, Daniel A., Schönbrunn, Ernst, Georg, Gunda I. · 2023 · Nature Communications

Abstract

Compared to most ATP-site kinase inhibitors, small molecules that target an allosteric pocket have the potential for improved selectivity due to the often observed lower structural similarity at these distal sites. Despite their promise, relatively few examples of structurally confirmed, high-affinity allosteric kinase inhibitors exist. Cyclin-dependent kinase 2 (CDK2) is a target for many therapeutic indications, including non-hormonal contraception. However, an inhibitor against this kinase with exquisite selectivity has not reached the market because of the structural similarity between CDKs. In this paper, we describe the development and mechanism of action of type III inhibitors that bind CDK2 with nanomolar affinity. Notably, these anthranilic acid inhibitors exhibit a strong negative cooperative relationship with cyclin binding, which remains an underexplored mechanism for CDK2 inhibition. Furthermore, the binding profile of these compounds in both biophysical and cellular assays demonstrate the promise of this series for further development into a therapeutic selective for CDK2 over highly similar kinases like CDK1. The potential of these inhibitors as contraceptive agents is seen by incubation with spermatocyte chromosome spreads from mouse testicular explants, where they recapitulate Cdk2 -/- and Spdya -/- phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-38732-x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 53

  1. Pan, Z. et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2, 58–61 (2007). · DOI · Paper page
  2. Teng, M. et al. Development of CDK2 and CDK5 dual degrader TMX-2172. Angew. Chem. Int. Ed. Engl. 59, 13865–70 (2020). · DOI
  3. Jia, Y. et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534, 129–132 (2016). · DOI · Paper page
  4. To, C. et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Disco. 9, 926–43 (2019). · DOI · Paper page
  5. To, C. et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat. Cancer 3, 402–417 (2022). · DOI
  6. Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–76 (2014). · DOI · Paper page
  7. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012). · DOI · Paper page
  8. Dummer, R. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 19, 603–15 (2018). · DOI · Paper page
  9. Roskoski, R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharm. Res. 165, 105463 (2021). · DOI · Paper page
  10. Rea, D. et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138, 2031–41 (2021). · DOI · Paper page
  11. Pan, Y. & Mader, M. M. Principles of kinase allosteric inhibition and pocket validation. J. Med. Chem. 65, 5288–99 (2022). · DOI
  12. Laufkotter, O., Hu, H., Miljkovic, F. & Bajorath, J. Structure- and similarity-based survey of allosteric kinase inhibitors, activators, and closely related compounds. J. Med. Chem. 65, 922–34 (2022). · DOI
  13. Berthet, C., Aleem, E., Coppola, V., Tessarollo, L. & Kaldis, P. Cdk2 knockout mice are viable. Curr. Biol. 13, 1775–1785 (2003). · DOI · Paper page
  14. Ortega, S. et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35, 25–31 (2003). · DOI · Paper page
  15. Faber, E. B., Wang, N. & Georg, G. I. Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception. Biol. Reprod. 103, 357–67 (2020). · DOI
  16. McGrath, D. A. et al. Structural basis of divergent cyclin-dependent kinase activation by Spy1/RINGO proteins. EMBO J. 36, 2251–62 (2017). · DOI
  17. Mikolcevic, P. et al. Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope. Nat. Commun. 7, 11084 (2016). · DOI
  18. Merrick, K. A. et al. Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol. Cell 42, 624–636 (2011). · DOI
  19. Betzi, S. et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 6, 492–501 (2011). · DOI · Paper page
  20. Faber, E. B. et al. Cooperativity between orthosteric inhibitors and allosteric inhibitor 8-anilino-1-naphthalene sulfonic acid (ANS) in cyclin-dependent kinase 2. ACS Chem. Biol. 15, 1759–64 (2020). · DOI
  21. Weber, G. & Young, L. B. Fragmentation of bovine serum albumin by pepsin: I. The origin of the acid expansion of the albumin molecule. J. Biol. Chem. 239, 1415–1423 (1964). · DOI · Paper page
  22. Stryer, L. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescent probe of non-polar binding sites. J. Mol. Biol. 13, 482–495 (1965). · DOI · Paper page
  23. Laurence, D. J. Interactions of calf-thymus histone fractions in aqueous solution with 8-anilinonaphthalene-1-sulphonic acid. Biochem. J. 99, 419–426 (1966). · doi:10.1042/bj0990419
  24. Brand, L., Gohlke, J. R. & Rao, D. S. Evidence for binding of rose bengal and anilinonaphthalenesulfonates at the active site regions of liver alcohol dehydrogenase. Biochemistry 6, 3510–3518 (1967). · doi:10.1021/bi00863a024
  25. Schonbrunn, E., Eschenburg, S., Luger, K., Kabsch, W. & Amrhein, N. Structural basis for the interaction of the fluorescence probe 8-anilino-1-naphthalene sulfonate (ANS) with the antibiotic target MurA. Proc. Natl Acad. Sci. USA 97, 6345–6349 (2000). · DOI · Paper page
  26. Martin, M. P. et al. A novel approach to the discovery of small-molecule ligands of CDK2. Chembiochem 13, 2128–2136 (2012). · DOI
  27. Faber, E. B. et al. Screening through lead optimization of high affinity, allosteric cyclin-dependent kinase 2 (CDK2) inhibitors as male contraceptives that reduce sperm counts in mice. J. Med. Chem. 66, 1928–40 (2023). · DOI
  28. Nepali, K., Lee, H. Y. & Liou, J. P. Nitro-group-containing drugs. J. Med. Chem. 62, 2851–93 (2019). · DOI · Paper page
  29. Wood, D. J. et al. Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition. Cell Chem. Biol. 26, 1–10 (2018).
  30. Kim, D. M., Yang, K. & Yang, B. S. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A. Exp. Mol. Med. 35, 421–430 (2003). · DOI
  31. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013). · DOI · Paper page
  32. Schmidt, T. et al. ProteomicsDB. Nucleic Acids Res. 46, D1271–D1281 (2018). · DOI · Paper page
  33. Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021). · DOI · Paper page
  34. Parry, D. et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 9, 2344–2353 (2010). · DOI · Paper page
  35. Roskoski, R. Jr Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharm. Res. 107, 249–75 (2016). · DOI · Paper page
  36. Au-Yeung, G. et al. Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin. Cancer Res. 23, 1862–74 (2017). · DOI
  37. Viera, A. et al. CDK2 is required for proper homologous pairing, recombination and sex-body formation during male mouse meiosis. J. Cell Sci. 122, 2149–2159 (2009). Pt 12. · DOI
  38. Tu, Z. et al. Speedy A-Cdk2 binding mediates initial telomere-nuclear envelope attachment during meiotic prophase I independent of Cdk2 activation. Proc. Natl Acad. Sci. USA 114, 592–597 (2017). · DOI
  39. Kalra, S., Joshi, G., Munshi, A. & Kumar, R. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Eur. J. Med. Chem. 142, 424–58 (2017). · DOI
  40. Merrick, K. A. et al. Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol. Cell 32, 662–672 (2008). · DOI · Paper page
  41. Zhang, J. et al. Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells. Nat. Commun. 13, 2835 (2022). · DOI
  42. Pauli, G. F. et al. Importance of purity evaluation and the potential of quantitative (1)H NMR as a purity assay. J. Med. Chem. 57, 9220–9231 (2014). · DOI · Paper page
  43. Pauli, G. F. et al. Correction to Importance of Purity Evaluation and the Potential of Quantitative 1H NMR as a Purity Assay. J. Med. Chem. 58, 9061–9061 (2015). · doi:10.1021/acs.jmedchem.5b01667
  44. Schonbrunn, E. et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J. Med. Chem. 56, 3768–3782 (2013). · DOI
  45. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D. Biol. Crystallogr. 66, 133–144 (2010). Pt 2. · DOI · Paper page
  46. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658–674 (2007). Pt 4. · DOI · Paper page
  47. Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. D. Biol. Crystallogr. 65, 1074–1080 (2009). Pt 10. · DOI · Paper page
  48. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213–221 (2010). Pt 2. · DOI · Paper page
  49. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126–2132 (2004). Pt 12 Pt 1. · DOI · Paper page
  50. Wiseman, T., Williston, S., Brandts, J. F. & Lin, L.-N. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 179, 131–137 (1989). · DOI · Paper page
  51. Schaaf, T. M. et al. High-throughput spectral and lifetime-based FRET screening in living cells to identify small-molecule effectors of SERCA. SLAS Disco. 22, 262–73 (2017). · DOI
  52. Jafari, R. et al.The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100–2122 (2014). · DOI · Paper page
  53. Chen, Y. et al. The SUN1-SPDYA interaction plays an essential role in meiosis prophase I. Nat. Commun. 12, 3176 (2021). · DOI

Cited by

See all 54

Metadata

Authors
Faber, E. B., Sun, L., Tang, J., Roberts, E., Ganeshkumar, S., Wang, N., Rasmussen, D., Majumdar, A., Hirsch, L. E., John, K., Yang, A., Khalid, H., Hawkinson, J. E., Levinson, N. M., Chennathukuzhi, V., Harki, D. A., Schönbrunn, E., & Georg, G. I.
Venue
Nature Communications
Published
2023-06-03
Volume
14
Issue
1
ISSN
2041-1723
Cited by
54
References
1
Language
en
Licence
Funders
  • U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R61 HD099743, HHSN27520180007I, R01 HD080431)
  • Minnesota Ovarian Cancer Alliance (NA)
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM008244, T32 GM132029, R01 GM121515)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30 CA232303)
  • National Institute for General Medical Sciences
  • U.S. Department of Defense (W81XWH-19-1-0336, W81XWH-21-1-0674)
  • Fulbright Association (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding. https://app.cochat.ai/papers/10.1038/s41467-023-38732-x
The paper
Faber, E. B., Sun, L., Tang, J., Roberts, E., Ganeshkumar, S., Wang, N., Rasmussen, D., Majumdar, A., Hirsch, L. E., John, K., Yang, A., Khalid, H., Hawkinson, J. E., Levinson, N. M., Chennathukuzhi, V., Harki, D. A., Schönbrunn, E., & Georg, G. I. (2023). Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding. Nature Communications. https://doi.org/10.1038/s41467-023-38732-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.